Review covers oral IL-23 receptor antagonist icotrokinra for inflammatory bowel disease

The wire

1. 01The September 24 review focuses on icotrokinra, an orally delivered peptide antagonist of the IL-23 receptor, in inflammatory bowel disease.
2. 02Oral peptide delivery for a target usually addressed by injectable antibodies is of interest to clinicians tracking macrocyclic and oral peptide drug development.
3. 03Only the title and citation details are available; efficacy, dosing and development stage conclusions are not stated here.

From the source

Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra

Expert opinion on emerging drugs · 2026 Sep 24 · Noviello D, Caprioli F, Noor NM et al.